List of Excipients in Branded Drug RIZATRIPTAN BENZOATE

Generic Drugs Containing RIZATRIPTAN BENZOATE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	rizatriptan benzoate	0093-7471	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals USA Inc	rizatriptan benzoate	0093-7471	LACTOSE MONOHYDRATE
Teva Pharmaceuticals USA Inc	rizatriptan benzoate	0093-7471	MAGNESIUM STEARATE
Teva Pharmaceuticals USA Inc	rizatriptan benzoate	0093-7471	SODIUM STARCH GLYCOLATE TYPE A POTATO

What are the Most Frequently-Used Excipients in RIZATRIPTAN BENZOATE?

# Of NDCs	Excipient
1	ACESULFAME POTASSIUM
4	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
23	ASPARTAME
1	CALCIUM SILICATE

Rizatriptan Benzoate Excipient Strategy and Commercial Opportunities

Last updated: August 21, 2026

Rizatriptan benzoate is a mature, genericized 5-HT1B/1D serotonin receptor agonist with no meaningful FDA exclusivity remaining. Commercial value is concentrated in formulation execution: rapid oral disintegration, taste masking, moisture control, lactose-free or aspartame-free positioning, packaging, and differentiated patient convenience. New chemical-entity or biosimilar strategies have little relevance. The strongest opportunities are in orally disintegrating tablets, low-moisture packaging, pediatric and adolescent usability, and fixed-dose or co-packaged migraine products.

What is the FDA regulatory status of rizatriptan benzoate?

Rizatriptan benzoate is the benzoate salt of rizatriptan, marketed originally by Merck as Maxalt tablets and Maxalt-MLT orally disintegrating tablets.

Regulatory item	Status
Active ingredient	Rizatriptan, supplied as rizatriptan benzoate
Therapeutic class	Triptan; 5-HT1B/1D receptor agonist
Original U.S. product	Maxalt
Original U.S. approval	1998
Dosage forms	Immediate-release tablets and orally disintegrating tablets
Prescription status	Prescription drug
Generic pathway	Abbreviated New Drug Application, or ANDA
Biologic status	Not applicable
Biosimilar pathway	Not applicable
FDA exclusivity	Expired
Current commercial structure	Multiple generic suppliers and legacy brand products

The FDA-approved indications include acute treatment of migraine with or without aura in adults. Labeling also includes use in pediatric patients in specified age and weight groups, subject to product-specific labeling and dosing limitations.[1]

Rizatriptan is not intended for migraine prevention. Key safety restrictions include cardiovascular contraindications, recent use of another triptan or ergot-containing product, uncontrolled hypertension, and use with monoamine oxidase-A inhibitors. Propranolol coadministration requires a reduced rizatriptan dose because propranolol increases rizatriptan exposure.[1]

What patents protect rizatriptan benzoate?

The original rizatriptan compound and product patents no longer provide a meaningful barrier to generic development in the United States. The relevant patent estate was associated with Merck’s Maxalt products and included compound, pharmaceutical composition, and dosage-form claims.

When does rizatriptan lose exclusivity?

Rizatriptan lost practical U.S. market exclusivity years ago. The original New Chemical Entity exclusivity period ended in the early 2000s, while the principal patent protection expired later. Generic rizatriptan products entered the U.S. market during the 2010 period.

Exclusivity category	Commercial impact
New Chemical Entity exclusivity	Expired
Original compound patent protection	Expired
Pediatric exclusivity	Expired
Formulation and orally disintegrating tablet protection	Expired or no longer commercially blocking
Orange Book generic-blocking protection	No material current barrier for standard products

The business implication is direct: an applicant developing a conventional 5 mg or 10 mg rizatriptan tablet is competing on cost, supply reliability, bioequivalence execution, and channel access rather than on patent exclusivity.

What is the Orange Book status of rizatriptan?

The FDA Orange Book remains the relevant source for listed patents, exclusivity codes, and reference-listed drug information. The branded Maxalt patent estate is no longer a practical barrier to routine ANDA development. Applicants should still review the current Orange Book entry and any applicable patent certifications at filing because product listings and regulatory records can change.[2]

For a new formulation, freedom-to-operate analysis should extend beyond the original Maxalt patents. Active third-party patents may cover:

• Orally disintegrating tablet manufacturing methods
• Taste-masking polymers
• Microcrystalline or porous carrier systems
• Film-coating technologies
• Unit-dose blister packaging
• Combination migraine therapies
• Device-assisted buccal or sublingual delivery

These later patents would not restore exclusivity to rizatriptan itself, but they could constrain a specific commercial formulation.

How many patents cover rizatriptan formulations?

The relevant patent landscape is better divided into four categories than counted as a single estate.

Patent category	Typical claim scope	Current strategic relevance
Compound patents	Rizatriptan chemical structure and salts	Low; expired
Composition patents	Tablets, excipient systems, dosage ranges	Low to moderate, depending on later filings
Orally disintegrating dosage-form patents	Fast dissolution, taste masking, low-water systems	Moderate for differentiated products
Combination or method-of-use patents	Rizatriptan with NSAIDs or other agents	Potentially relevant for new combinations

A developer should not assume that expired compound protection eliminates all formulation risk. A conventional generic can be clear of the original estate while a new ODT, buccal film, multiparticulate, or combination product remains exposed to later patents.

What excipients are used in rizatriptan benzoate products?

The reference products use different excipient strategies for conventional tablets and orally disintegrating tablets.

Conventional rizatriptan tablets

The conventional tablet platform generally uses standard direct-compression or dry-granulation excipients:

• Lactose monohydrate
• Microcrystalline cellulose
• Pregelatinized starch
• Colloidal silicon dioxide
• Magnesium stearate
• Colorants, where applicable

These ingredients support compactability, tablet strength, lubrication, powder flow, and rapid disintegration. The formulation is inexpensive and compatible with high-throughput tablet manufacturing.[3]

The main commercial limitation is lactose. Lactose-containing products are acceptable for most patients but create a differentiation opportunity for manufacturers targeting lactose-free portfolios, certain dietary requirements, or institutional formularies with standardized excipient policies.

Orally disintegrating tablets

Maxalt-MLT-type products use a low-water or rapidly dispersible matrix. Label information identifies excipients such as:

• Mannitol
• Glycine
• Gelatin
• Aspartame
• Peppermint flavor
• Other processing and tableting aids

Mannitol contributes bulk, mouthfeel, cooling sensation, and water-soluble tablet structure. Glycine can improve taste and mouthfeel. Gelatin supports the rapidly dispersible matrix used in certain freeze-dried or specialized ODT platforms. Aspartame and peppermint flavor address palatability but create labeling and patient-segmentation constraints.[4]

What excipient strategy is best for a new rizatriptan product?

The preferred strategy depends on the target product profile rather than the active ingredient alone.

Strategy 1: Low-cost conventional tablet

A conventional tablet remains the lowest-risk commercial option. The development target is a robust immediate-release product with:

• Comparable dissolution to the reference product
• High tabletability at 5 mg and 10 mg strengths
• Low friability
• Stable moisture profile
• Scalable commercial compression
• Minimal excipient count

Microcrystalline cellulose and pregelatinized starch provide a familiar platform. Crospovidone or croscarmellose sodium may be evaluated when faster disintegration is needed, although the final formula must preserve dissolution performance and avoid excessive tablet swelling.

The opportunity is strongest where the sponsor has manufacturing-cost advantages, reliable API sourcing, or an established generic sales channel.

Strategy 2: Lactose-free tablet

Replacing lactose with mannitol, dicalcium phosphate, microcrystalline cellulose, or a co-processed excipient can create a straightforward portfolio differentiator.

Mannitol is particularly attractive when the sponsor wants to use one excipient platform across conventional and orally disintegrating products. Dicalcium phosphate can improve compactability but may alter density, disintegration, and dissolution. Co-processed excipients can simplify development but may carry higher raw-material costs.

A lactose-free claim must be supported by supplier controls, manufacturing segregation, and validated analytical testing. The claim has more commercial relevance in specialty pharmacy, hospital purchasing, and selected consumer segments than in broad generic substitution alone.

Strategy 3: Aspartame-free ODT

Aspartame-free positioning addresses patients with phenylketonuria and consumers seeking to avoid artificial sweeteners. Suitable alternatives may include:

• Sucralose
• Acesulfame potassium
• Steviol glycosides
• Mannitol-based sweetness and cooling
• Natural or nature-identical flavors
• Ion-exchange resin taste masking

The principal technical issue is bitterness. Rizatriptan has a potent active-drug taste that can become prominent during oral dispersion. Sweetener substitution without a taste-masking system may produce an inferior product even if the tablet meets disintegration specifications.

Strategy 4: Rapid-disintegration ODT

A high-value ODT should target:

• Disintegration in less than 30 seconds
• Acceptable mouthfeel
• Minimal residue
• Low friability
• Stability under elevated humidity
• Unit-dose protection
• No requirement for water

The principal formulation options are:

1. Direct-compression ODT with superdisintegrants
2. Freeze-dried porous tablet
3. Molding or lyophilized matrix
4. Taste-masked multiparticulates compressed into a tablet
5. Thin oral film, if development and regulatory risk justify the platform

A freeze-dried product may provide superior dispersion but requires more complex manufacturing and moisture-protective packaging. Direct-compression ODTs reduce capital requirements but may have greater tradeoffs between mechanical strength and rapid disintegration.

What formulation patents could protect a new rizatriptan product?

Formulation patents are most defensible when they claim measurable technical performance rather than a simple substitution of one conventional excipient for another.

Potential claim areas include:

• A defined ratio of rizatriptan benzoate to mannitol and superdisintegrant
• A taste-masked rizatriptan particle with a polymeric coating
• A low-moisture ODT with a specified disintegration time
• A composition with improved stability under high humidity
• A lactose-free or aspartame-free formulation with equivalent dissolution
• A multilayer tablet separating rizatriptan from incompatible excipients
• A unit-dose blister system that preserves tablet integrity
• A solid dispersion or amorphous formulation with improved dissolution

Weak patent positions usually involve routine excipient replacements without unexpected performance. A stronger application should include comparative data against the reference product and credible evidence of improved taste, stability, disintegration, or manufacturability.

What manufacturing and intellectual-property barriers exist?

Rizatriptan is not difficult because of complex molecular synthesis. The principal barriers are formulation and supply-chain execution.

API and salt control

Rizatriptan benzoate requires control of:

• Salt stoichiometry
• Polymorphic or solid-state behavior
• Particle-size distribution
• Residual solvents
• Water content
• Assay and impurity profile
• Content uniformity at the low 5 mg dose

The low active loading increases the importance of blend uniformity and segregation control. A formulation that performs well at 10 mg may require separate process validation at 5 mg.

ODT manufacturing

ODT products face tighter process controls than standard tablets. Risks include:

• Capping and friability
• Sensitivity to humidity
• Uneven flavor distribution
• Poor taste masking
• Inconsistent disintegration
• Packaging-induced moisture uptake
• Mechanical damage during bottling

Blister packaging is generally preferable for fragile or moisture-sensitive ODTs. Bottles may reduce packaging cost but can create greater exposure to repeated opening and closing.

What generic entry risks exist for rizatriptan?

The patent risk is low for standard tablets, but commercial and regulatory risks remain.

Risk	Conventional tablet	ODT
Patent blocking risk	Low	Low to moderate
Bioequivalence complexity	Moderate	Moderate to high
Taste and mouthfeel risk	Low	High
Moisture stability risk	Moderate	High
Manufacturing complexity	Low	Moderate to high
Price erosion risk	High	High
Differentiation potential	Low	Moderate
Packaging cost	Low	Moderate to high

An ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence to the applicable reference product. For an ODT, rapid disintegration does not eliminate the need for systemic bioequivalence. The product also must meet dosage-form, labeling, stability, and manufacturing requirements under FDA regulations and applicable product-specific guidance.[5]

Which companies are challenging the rizatriptan market?

The U.S. market has historically included multiple generic manufacturers, including large generic companies and contract-manufacturing suppliers. Competition is generally based on:

• Wholesale acquisition cost
• Medicaid and commercial rebate strategy
• Pharmacy benefit manager access
• Supply continuity
• Authorized-generic relationships
• National versus regional distribution
• Availability of both 5 mg and 10 mg strengths

No biosimilar competition exists because rizatriptan is a chemically synthesized small molecule. A new entrant would compete against generic tablets rather than biosimilar products.

The most defensible commercial position is unlikely to come from another undifferentiated tablet. An ODT, lactose-free product, aspartame-free product, or reliably supplied dual-strength portfolio offers more room for channel-based differentiation.

What licensing deals and settlement agreements affect rizatriptan?

The original Maxalt commercialization was associated with Merck’s ownership and development of rizatriptan. Generic entry followed expiration of the relevant exclusivity and patent barriers. Historical patent litigation and Paragraph IV activity affected the timing of generic competition, but those events no longer create a current market-entry barrier for ordinary rizatriptan products.

For a new entrant, the more important licensing questions concern technology rather than the active ingredient:

• ODT manufacturing platforms
• Taste-masking technologies
• Co-processed excipient systems
• Moisture-resistant blister systems
• Contract development and manufacturing capacity
• Combination-product rights

A license may be economically justified where it avoids investment in lyophilization, proprietary taste masking, or specialized packaging. It is less attractive for a standard compressed tablet because the underlying technology is widely available.

How does rizatriptan compare with competing triptans?

Product	Key formulation opportunity	Commercial position
Rizatriptan	ODT, lactose-free tablet, rapid disintegration	Mature generic market
Sumatriptan	Tablets, nasal spray, injection	Broader delivery-form competition
Zolmitriptan	Tablets, ODT, nasal spray	Strong ODT comparison
Eletriptan	Conventional tablet	Brand and generic differentiation
Naratriptan	Lower-dose tablet	Longer-duration positioning
Frovatriptan	Tablet	Longer half-life and menstrual-migraine use
Ubrogepant and rimegepant	Oral small-molecule CGRP products	Newer, higher-value competitors

Rizatriptan’s formulation advantage is speed and convenience, not duration of action. Its ODT format competes most directly with zolmitriptan ODT and other rapid-use migraine products. Newer CGRP antagonists compete on tolerability, absence of vasoconstrictive triptan activity, and broader eligibility, but they generally have a higher cost base and different patent profiles.

What revenue exposure does rizatriptan create?

Rizatriptan has limited brand-revenue potential because generic substitution is established. Revenue opportunity depends on product architecture.

Low-value opportunity

A standard tablet may generate volume but faces rapid price erosion, tender pressure, and limited prescriber-driven differentiation. The most important variables are manufacturing cost, fill-rate performance, and payer access.

Moderate-value opportunity

An ODT can support higher gross margins if it provides:

• Better adherence to prescribed dosing
• Convenient administration without water
• Reliable taste performance
• Strong packaging integrity
• Consistent availability
• Pediatric or adolescent usability within approved labeling

The premium must be supported by demonstrated patient or channel value. A nominal excipient change without a visible benefit is unlikely to sustain pricing.

Higher-value adjacent opportunities

The strongest strategic opportunities may involve:

• Rizatriptan plus an NSAID in a fixed-dose combination
• Co-packaged acute migraine regimens
• Specialty pharmacy and telehealth distribution
• Private-label ODT products
• International products adapted to local excipient restrictions
• Contract development of migraine ODT platforms usable with other APIs

Combination products require separate regulatory, clinical, labeling, and patent analysis. They may create new patentable subject matter but also introduce additional safety and claim risks.

What is the best commercial excipient strategy?

For a U.S. generic entrant, the strongest sequence is:

1. Develop a conventional lactose-free 5 mg and 10 mg tablet for low-cost market access.
2. Use a common excipient platform where possible to reduce manufacturing complexity.
3. Develop an aspartame-free ODT with rapid disintegration and strong taste performance.
4. Use unit-dose moisture-protective blister packaging.
5. Build patent claims around demonstrated taste, stability, and performance advantages.
6. Support the product with reliable supply rather than relying on a premium claim alone.

The conventional tablet provides volume and manufacturing efficiency. The ODT provides differentiation. A dual-product portfolio reduces dependence on a single price segment.

Key Takeaways

• Rizatriptan benzoate is a mature small-molecule drug with expired U.S. exclusivity.
• Standard tablets face low patent risk and high price competition.
• The principal commercial opportunity is formulation differentiation.
• ODTs offer the strongest platform for value creation, but taste masking and humidity protection are critical.
• Mannitol, glycine, superdisintegrants, flavor systems, and taste-masking technologies are central excipient tools.
• Lactose-free and aspartame-free products can address defined patient and channel segments.
• No biosimilar pathway applies.
• New formulation patents should claim measurable technical advantages rather than routine excipient substitutions.
• Blister packaging is generally more attractive than bottles for fragile or moisture-sensitive ODTs.
• Fixed-dose combinations and co-packaged migraine therapies offer higher upside but carry greater regulatory and patent complexity.

FAQs

Can rizatriptan benzoate be formulated without lactose?

Yes. Lactose can be replaced with mannitol, microcrystalline cellulose, dicalcium phosphate, or a co-processed excipient system, subject to dissolution, stability, content-uniformity, and manufacturability testing.

Is an orally disintegrating rizatriptan tablet patentable?

Potentially. Patentability is strongest when the formulation demonstrates unexpected improvements in taste, humidity stability, disintegration, mechanical strength, or bioavailability.

Does rizatriptan benzoate require a biosimilar application?

No. Rizatriptan is a chemically synthesized small molecule. A generic version is submitted through the ANDA pathway, not the biosimilar pathway.

What packaging is best for rizatriptan ODT products?

A high-barrier unit-dose blister is generally the preferred option when the ODT has meaningful sensitivity to moisture, friability, or mechanical damage.

Can a new rizatriptan product claim faster migraine relief based only on rapid tablet disintegration?

No. Rapid in-vitro disintegration alone does not establish faster clinical relief. Such a claim would require appropriate clinical and regulatory support.

References

1. U.S. Food and Drug Administration. (2023). Maxalt and Maxalt-MLT prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. DailyMed. (2024). Rizatriptan benzoate tablet: Product labeling and inactive ingredients. National Library of Medicine.
4. DailyMed. (2024). Maxalt-MLT rizatriptan benzoate orally disintegrating tablet: Product labeling. National Library of Medicine.
5. U.S. Food and Drug Administration. (2018). Rizatriptan benzoate tablets: Product-specific guidance for industry.